{"prompt": "['Novartis', 'Confidential', 'Page 106', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '22 Appendix 10: Low, medium and high Daily Doses of Inhaled', 'Glucocorticosteroids for Adults\u00b9', 'Drug', 'Total Daily Dose (g/day)', 'Low', 'Medium', 'High', 'Beclomethasone dipropionate - CFC\u00b2', '200-500', '> 500 - 1000', '> 1000', 'Beclomethasone dipropionate - HFA', '100-200', '> 200 - 400', '> 400', 'Budesonide- DPI', '200-400', '> 400 - 800', '> 800', 'Ciclesonide - HFA', '80-160', '> 160 - 320', '> 320', 'Fluticasone Furoate - DPI\u00b3', 'NA', '100', '200', 'Fluticasone propionate - DPI', '100-250', '> 250 - 500', '> 500', 'Fluticasone propionate - HFA', '100-250', '> 250 - 500', '> 500', 'Mometasone furoate', '110-220', '>220-440', '440', 'Triamcinolone acetonide', '400-1000', '> 1000 - 2000', '> 2000', '1,3 Categories based on GINA 2017 with exception of Fluticasone Furoate which is based on the Summary of Product', 'Characteristics of Relvar\u00ae ElliptaR', '2Beclomethasone dipropionate CFC is included for comparison with older literature.', 'CFC: chlorofluorocarbon propellant; DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant.']\n\n###\n\n", "completion": "END"}